


# ANALYSIS OF EPIGENETICS AND CHROMATIN STATES IN NORMAL AND CANCER GENOMES

Valentina BOEVA


Institut Curie, Inserm U900, Mines ParisTech




# DNA is bound around histone proteins to form chromatin




1 Mb of chromatin




# There are many various sequence patterns and motifs in the genome





Genome



## Genomic patterns




# Pattern and motifs (directly or indirectly) affect functional properties of genomic regions







# Epigenetic profiles = combination of CpG methylation of DNA and histone modifications




# Histone modifications have direct effect on gene transcription









- Histone modifications



# Histone modifications have direct effect on gene transcription



Density of histone modification signal




Correlation of different histone marks with gene expression


Gene Expression Level



# Histone modifications form groups and indicate distinct chromatin states




- Histone modifications, histone variants, binding sites (Pol II, CTCF, p300,...) → chromatin states






# Histone modifications form groups and indicate distinct chromatin states




- Histone modifications, histone variants, binding sites (Pol II, CTCF, p300,...) → **chromatin states**




Pair-wise correlations of allelic signal within single genes (below the diagonal) or within individual ChromHMM segments across the whole genome for selected DNase-seq and histone modification ChIP-seq assays


# Histone modifications form groups and indicate distinct chromatin states




- Histone modifications, histone variants, binding sites (Pol II, CTCF, p300,...) → chromatin states



# Histone modifications form groups and indicate distinct chromatin states





51 states



Input chromatin mark information and resulting chromatin state annotation for a 120-kb region of human chromosome 7 surrounding the CAPZA2 gene


# Histone modifications form groups and indicate distinct chromatin states




Chromatin mark combinations associated with each state and brief description of biological state function and interpretation



# Hidden Markov Models allow annotating chromatin states




- Probabilistic parameters of a Hidden Markov Model (HMM)







# Hidden Markov Models allow annotating chromatin states




- Probabilistic parameters of a Hidden Markov Model (HMM)




# Hidden Markov Models allow annotating chromatin states




- Probabilistic parameters of a Hidden Markov Model (HMM)




# Hidden Markov Models allow annotating chromatin states




- Probabilistic parameters of a Hidden Markov Model (HMM)




# Hidden Markov Models allow annotating chromatin states




- Probabilistic parameters of a Hidden Markov Model (HMM)



# Hidden Markov Models allow annotating chromatin states




- Probabilistic parameters of a Hidden Markov Model (HMM)







# Hidden Markov Models allow annotating chromatin states




- Probabilistic parameters of a Hidden Markov Model (HMM)




# Hidden Markov Models allow annotating chromatin states




- Probabilistic parameters of a Hidden Markov Model (HMM)




# Hidden Markov Models allow annotating chromatin states




- Probabilistic parameters of a Hidden Markov Model (HMM)




# Hidden Markov Models allow annotating chromatin states




- Probabilistic parameters of a Hidden Markov Model (HMM)



# Hidden Markov Models allow annotating chromatin states




- Probabilistic parameters of a Hidden Markov Model (HMM)







# Hidden Markov Models allow annotating chromatin states




- Probabilistic parameters of a Hidden Markov Model (HMM)




# Hidden Markov Models allow annotating chromatin states




- Probabilistic parameters of a Hidden Markov Model (HMM)




# Hidden Markov Models allow annotating chromatin states




- Probabilistic parameters of a Hidden Markov Model (HMM)




# Hidden Markov Models allow annotating chromatin states




- Probabilistic parameters of a Hidden Markov Model (HMM)




# Hidden Markov Models allow annotating chromatin states




- Probabilistic parameters of a Hidden Markov Model (HMM)



# Hidden Markov Models allow annotating chromatin states




- Hidden Markov Model = we cannot observe the states







# Hidden Markov Models allow annotating chromatin states




- Probabilistic parameters of a Hidden Markov Model (HMM)




# Hidden Markov Models allow annotating chromatin states




- Probabilistic parameters of a Hidden Markov Model (HMM)




# Hidden Markov Models allow annotating chromatin states




- Probabilistic parameters of a Hidden Markov Model (HMM)




# Hidden Markov Models allow annotating chromatin states




- Probabilistic parameters of a Hidden Markov Model (HMM)




# Hidden Markov Models allow annotating chromatin states




- Probabilistic parameters of a Hidden Markov Model (HMM)



# Hidden Markov Models allow annotating chromatin states




- Probabilistic parameters of a Hidden Markov Model (HMM)







# Hidden Markov Models allow annotating chromatin states




- Probabilistic parameters of a Hidden Markov Model (HMM)




# Hidden Markov Models allow annotating chromatin states




- Probabilistic parameters of a Hidden Markov Model (HMM)



# Hidden Markov Models allow annotating chromatin states



- States change in time, but we do not observe them
- States define our observations
- First order HMM: state  $(t+1)$  depends only on the previous state  $(t)$



Decoding question in HMM:

Solution: Viterbi Algorithm

known

$x$  — states **to be defined!**



$y$  — possible observations

$a$  — state transition probabilities

$b$  — output probabilities



# Histone modifications = observations

## Functional regions = states




Input chromatin mark information and resulting chromatin state annotation for a 120-kb region of human chromosome 7 surrounding the CAPZA2 gene

# Hidden Markov Models allow annotating chromatin states





Transition probabilities

Transition parameters





# Hidden Markov Models allow annotating chromatin states








# Hidden Markov Models allow annotating chromatin states




# Hidden Markov Models allow annotating chromatin states




Emission probabilities



# Hidden Markov Models allow annotating chromatin states



- **ChromHMM**: automating chromatin-state discovery and characterization



# How many states to select?


- Use your biological intuition
- Score each model based on the log likelihood of the model minus a penalization on the model complexity determined by the **Bayesian Information Criterion (BIC)** of one-half the number of parameters times the natural log of the number of intervals

"There are three kinds of lies: lies, damned lies, and statistics."





Benjamin Disraeli


# With chromatin states, one can predict gene expression




**a** CAGE poly(A)<sup>+</sup> K562 whole cell




# With chromatine states, one can predict gene expression **better than with TFBSs**



**b** CAGE poly(A)<sup>+</sup> K562 whole cell




Relative importance of variables





# The prediction of expression is done using linear regression model




- We try to predict:  
 $\log_2(Y_i)$ , where  $Y_i$  is expression value (based on CAGE poly-A experiment)
- using  
 $\log_2(X_{ij} + a_j)$ , where  $X_{ij}$  is normalized tag counts for chromatin feature  $j$  at gene  $i$  ( $a_j$  = pseudocount)

$$\log_2(Y_i) \approx \sum_{\text{chromatin feature } j} \alpha_j \log_2(X_{ij} + a_j) + \beta$$

Alternatively, it is possible to use Random Forests or multivariate adaptive regression splines (MARS).

# Methylation of CpG sites on DNA is also related to transcription



Addition of a methyl group to a cytosine within CpG di-nucleotide which are frequently located in the regulatory regions of genes


A mechanism for gene silencing:

- Preventing binding of regulatory factors
- Affecting chromatin status

Target gene **expressed**




Target gene **silenced**





(Fry, 2011)

# Bisulfite sequencing employed to detect methylation status of Cytosine




- Bisulfite treatment transforms unmethylated cytosine in uracil



# MAKING A GENOME MANUAL


Scientists in the Encyclopedia of DNA Elements Consortium have applied 24 experiment types (across) to more than 150 cell lines (down) to assign functions to as many DNA regions as possible — but the project is still far from complete.









# What is going on with epigenetic profiles in cancer?



- Do epigenetic states change compared to normal ancestral cells?
- Is there any global phenomenon related to epigenetics inherent to cancer cells?



# Histone and CpG-methyl modifying proteins are often mutated or deleted in cancer



Epigenome-modifying gene mutations in human cancer


| Gene                              | Cancer  | Frequency or stage of cancer           | Frequency of mutation (N) | Effect                          |
|-----------------------------------|---|--|---------------------------|---------------------------------|
| <b>Histone variants</b>           |   |  |                           |                                 |
| HIST1H1B                          | Colorectal cancer                             | Common                                 | 4% (24)                   |                                 |
| HIST1H1C                          | Non-Hodgkin's lymphoma                        | Common                                 | 7% (127)                  |                                 |
| H3F3A                             | Paediatric glioblastoma                       | Rare aggressive paediatric, high grade | 36% (90)                  | Prevents PTMs on H3K27 or H3K36 |
|                                   | Diffuse intrinsic pontine glioma              | Rare aggressive paediatric             | 60% (50)                  | Prevents PTMs on H3K27          |
| HIST1H3B                          | Diffuse intrinsic pontine glioma              | Rare aggressive paediatric             | 10% (50)                  | Prevents PTMs on H3K27          |
| <b>DNA methyltransferases</b>     |   |  |                           |                                 |
| DNMT1                             | Colorectal cancer                             |  | 2% (29)                   | Mutation                        |
| DNMT3A                            | AML   | Stage M4                               | 13.6% (66)                |                                 |
|                                   |   | Stage M5                               | 20.5% (112)               |                                 |
|                                   | AML   | Common                                 | 22.1% (261)               |                                 |
| <b>DNA demethylases</b>           |   |  |                           |                                 |
| TET2                              | BCR-ABL-negative myeloproliferative neoplasms | Rare form                              | 13% (239)                 |                                 |
|                                   |   | Common form                            | 50% (88)                  |                                 |
|                                   |   | Rare                                   | 26% (102)                 |                                 |
| IDH1                              | Anaplastic astrocytoma                        | Rare                                   | 73% (52)                  |                                 |
|                                   |   | Rare                                   | 90% (30)                  |                                 |
|                                   |   | Common                                 | 6.2% (385)                |                                 |
| IDH2                              | AML   | Common                                 | 8.6% (385)                |                                 |
|                                   |   |  |                           |                                 |
| <b>Histone acetyltransferases</b> |   |  |                           |                                 |
| EP300 (which encodes p300)        | Pancreas adenocarcinoma                       | Common form                            | 8% (24)                   | Mutation                        |
|                                   | DLBCL   | Common form                            | 10% (134)                 | Mutation                        |
|                                   | Follicular lymphoma                           | Uncommon form                          | 8.7% (46)                 | Mutation                        |
|                                   | Head and neck squamous cell cancer            | Common                                 | 11% (74)                  | Mutation                        |
|                                   | Transitional cell carcinoma (bladder)         | Common                                 | 13% (97)                  | Mutation                        |
| CREBBP (which encodes CBP)        | Ovary   | Common                                 | 3% (75)                   | Inactivated                     |
|                                   | Breast adenocarcinoma                         | Common                                 | 8% (183)                  | Gain of copy                    |
|                                   | Lung cancer                                   | Common                                 | 5.3% (95)                 | Mutation                        |
|                                   | DLBCL   | Common form                            | 22.4% (134)               | Mutation                        |
|                                   | DLBCL   | Common form                            | 18% (111)                 | Mutation                        |
|                                   | Follicular lymphoma                           | Uncommon form                          | 32.6% (46)                | Mutation                        |
|                                   | Relapsed ALL                                  |  | 10.3% (71)                | Mutation                        |
| ELP4                              | Breast adenocarcinoma                         | Common                                 | 13% (97)                  | Mutation                        |
|                                   |   | Common                                 | 4% (183)                  | Gain of copy                    |
| <b>Histone deacetylases</b>       |   |  |                           |                                 |
| HDAC4                             | Breast adenocarcinoma                         | Common                                 | 4% (24)                   | Mutation                        |
| HDAC9                             | Prostate adenocarcinoma                       | Common                                 | 42.9% (7)                 | Mutation                        |
| <b>Histone methyltransferases</b> |   |  |                           |                                 |
| SETD2                             | Renal clear cell carcinoma                    | Common                                 | 3% (407)                  | Mutation                        |
| MEN1                              | Pancreas neuroendocrine cancer                | Rare                                   | 44% (68)                  | Mutation                        |
|                                   | Parathyroid cancer                            | Rare                                   | 35% (185)                 | Mutation                        |
| MLL                               | Squamous cell lung cancer                     | Rare                                   | 3% (63)                   | Mutation                        |
|                                   | Transitional cell carcinoma (bladder)         | Common                                 | 7% (97)                   | Mutation                        |
|                                   | Mixed lineage leukaemia                       | Common                                 | 100% (definition)         | Fusion                          |

| Gene                                      | Cancer                                | Frequency or stage of cancer | Frequency of mutation (N) | Effect                   |          |
|---|---------------------------------------|------------------------------|---------------------------|--------------------------|----------|
| <b>Histone methyltransferases (cont.)</b> |                                       |                              |                           |                          |          |
| MLL2                                      | Renal clear cell carcinoma            | Common                       | 4% (407)                  | Mutation                 |          |
|   | Childhood medulloblastoma             | Rare                         | 8.7% (92)                 | Mutation                 |          |
|   | Childhood medulloblastoma             | Rare                         | 13.6% (88)                | Mutation                 |          |
|   | DLBCL                                 | Common form                  | 32% (37)                  | Mutation                 |          |
|   | DLBCL                                 | Common form                  | 22.8% (92)                | Mutation                 |          |
|   | Follicular lymphoma                   | Uncommon form                | 89% (35)                  | Mutation                 |          |
|   | Head and neck squamous cell cancer    | Common                       | 11% (74)                  | Mutation                 |          |
| MLL3                                      | Childhood medulloblastoma             | Rare                         | 3.4% (88)                 | Mutation                 |          |
|   | Transitional cell carcinoma (bladder) | Common                       | 5% (97)                   | Mutation                 |          |
|   | Colorectal cancer                     | Common                       | 20.8% (24)                |                          |          |
|   |                                       |                              |                           |                          |          |
| EZH2                                      | Non-Hodgkin's lymphoma                | Common                       | 7.8% (681)                | Mutations                |          |
|   | DLBCL                                 | Common form                  | 5.6% (107)                | Mutation                 |          |
|   | MDS and MPNs                          | Rare                         | 12% (219)                 | Mutations                |          |
|   | Myelofibrosis                         | Rare                         | 13% (30)                  | Mutations                |          |
|   | Follicular lymphoma                   | Uncommon form                | 12% (221)                 | Mutations                |          |
| <b>Histone demethylases</b>               |                                       |                              |                           |                          |          |
| KDM5C (also known as JARID1C)             | Renal clear cell carcinoma            | Common                       | 3% (407)                  | Mutation                 |          |
| KDM6A (also known as UTX)                 | Transitional cell carcinoma (bladder) | Common                       | 20% (97)                  | Mutation                 |          |
|   | Childhood medulloblastoma             | Rare                         | 3.2% (92)                 | Mutation                 |          |
| KDM2B                                     | DLBCL                                 | Uncommon form                | 7.4% (54)                 | Mutation                 |          |
| <b>Chromatin remodelling factors</b>      |                                       |                              |                           |                          |          |
| ARID1A                                    | Pancreas adenocarcinoma               | Common                       | 8% (24)                   | Mutation                 |          |
|   | Ovarian clear cell carcinoma          | Rare                         | 57% (42)                  | Mutation                 |          |
|   | Ovarian clear cell carcinoma          | Rare                         | 46% (119)                 | Mutation                 |          |
|   | Endometrial cancer                    | Common                       | 30% (33)                  | Mutation                 |          |
|   | Transitional cell carcinoma (bladder) | Common                       | 13% (97)                  | Mutation                 |          |
|   | Hepatocellular carcinoma              | Common                       | 16.8% (125)               | Mutation                 |          |
|   | Colorectal adenocarcinoma             | Hypermutated                 |                           | 37% (30)                 | Mutation |
|   |                                       | Non-hypermutated             |                           | 5% (165)                 |          |
| ARID1B                                    | Breast adenocarcinoma                 | Common                       | 5% (100)                  | Mutation                 |          |
| ARID2                                     | Hepatocellular carcinoma              | Common                       | 5.6% (125)                | Mutation                 |          |
|   | Melanoma                              | Common                       | 9% (121)                  | Nonsense mutation        |          |
| CHD1                                      | Prostate adenocarcinoma               | Common                       | 42.9% (7)                 | Mutation                 |          |
| CHD5                                      | Prostate adenocarcinoma               | Common                       | 42.9% (7)                 | Mutation                 |          |
| PBRM1                                     | Clear cell renal carcinoma            | Common                       | 41% (227)                 | Mutation                 |          |
| ATRX                                      | Pancreas neuroendocrine cancer        | Rare                         | 25% (68)                  | Mutation                 |          |
| DAXX                                      | Pancreas neuroendocrine cancer        | Rare                         | 17.6% (68)                | Mutation                 |          |
| SMARCD1                                   | Breast adenocarcinoma                 | Common                       | 4% (100)                  | Mutation                 |          |
| SMARCB1 (also known as SNF5 and INI1)     | Malignant rhabdoid cancer             | Rare                         | 100% (29)                 | Loss of copy or mutation |          |
| SMARCA4                                   | Childhood medulloblastoma             | Rare                         | 4.3% (92)                 | Mutation                 |          |




# Changes in CpG methylation are common in cancer


- Loss of imprinting (e.g. of *IGF2*)
- Hypermethylation of CpG islands of tumor suppressor genes
- Genome-wide DNA hypomethylation



# DNA methylation status can be associated with tumor aggressiveness




ER- $\alpha$  methylation  
Skin cancer



Kaplan–Meier curves showing the correlation of pre-biochemotherapy serum ER- $\alpha$  methylation status with OS ( $p = 0.003$ )


RASSF1A methylation  
Skin cancer




Kaplan–Meier survival curves of biochemotherapy patients: Correlation of pre-BC serum RASSF1A methylation BM with overall survival ( $p = .013$ ).

# LRES & LOCKs: Global changes in epigenetic patterns in cancer



- Histone modification patterns are altered in human tumors
  - Long Range Epigenetic Silencing (LRES)
  - Large organized chromatin-lysine-(K) modifications (LOCKs)



# Example of LRES/LOCK of *HOXD* gene cluster in bladder cancer




Enrichment in repressive histone mark **H3K27me3**



Cluster of *HOXD* genes repressed by epigenetic mechanisms

# Histone modifications can predict the prognosis of various cancers




| Study                             | Cancer type | Histone Modifications                                 |
|-----------------------------------|-------------|---|
| Song <i>et al.</i> 2012           | Lung        | H3K9ac, H3K9me3, H4K16ac                              |
| Barlési <i>et al.</i> 2007        | Lung        | H3K4me2, H3K9ac                                       |
| Van Den Broeck <i>et al.</i> 2008 | Lung        | H4K5ac, H4K8ac, H4K12ac, H4K16ac, H4K20me3            |
| Seligson <i>et al.</i> 2009       | Lung        | H3K4me2, H3K18ac                                      |
| Seligson <i>et al.</i> 2005       | Prostate    | H3K4me2, H3K18ac                                      |
| Ellinger <i>et al.</i> 2010b      | Prostate    | H3K4me1, H3K9me2, H3K9me3, H3Ac, H4Ac                 |
| Behbahani <i>et al.</i> 2012      | Prostate    | H4K20me1, H4K20me2                                    |
| Bianco-Miotto <i>et al.</i> 2010  | Prostate    | H3K4me2, H3K18ac                                      |
| Ellinger <i>et al.</i> 2012       | Prostate    | H3K27me3  |
| Elsheikh <i>et al.</i> 2009       | Breast      | H3K18ac, H4K12ac, H3K4me2, H4K20me3, H4R3me2, H4K16ac |
| Leszinski <i>et al.</i> 2012      | Breast      | H3K9me3, H4K20me3                                     |
| Müller-Tidow <i>et al.</i> 2010   | Leukemia    | H3K9me3   |
| Park <i>et al.</i> 2008           | Stomach     | H3K9me3   |
| Zhang <i>et al.</i> 2009          | Stomach     | H3K27me3  |
| Tzao <i>et al.</i> 2009           | Esophagus   | H3K18ac, H4R3me2, H3K27me3                            |
| I <i>et al.</i> 2010              | Esophagus   | H3K18ac, H4R3me2                                      |
| Ellinger <i>et al.</i> 2010a      | Kindeg      | H3K4me1, H3K4me2, H3K4me3                             |
| Rogenhofer <i>et al.</i> 2012a    | Kidney      | H3K9me1   |
| Rogenhofer <i>et al.</i> 2012b    | Kidney      | H3K27me1, H3K27me2, H3K27me3                          |
| He <i>et al.</i> 2012             | Liver       | H3K4me3   |
| Cai <i>et al.</i> 2011            | Liver       | H3K27me3  |
| Manuyakorn <i>et al.</i> 2010     | Pancreas    | H3K4me2, H3K9me2, H3K18ac                             |


Res

Am J Cancer Res

# One should apply specific methods to detect histone modifications in cancer





- Specific feature of cancer samples: large copy number changes





# Standard methods for signal detection can miss signal in regions of loss in cancer



Copy number profile

Peaks predicted by tools:


## MACS

Zhang, Y. et al. (2008) *Genome Biol.*, **9**, R137


## SICER

Zang, C. et al. (2009) *Bioinformatics*, **25**, 1952–1958.

# Solution: explicit normalization for copy number status





- Hidden Markov model after **correction** of ChIP-seq signal for **copy number** and **GC-content** bias




Software:  
HMCan

[www.cbrc.kaust.edu.sa/hmcan](http://www.cbrc.kaust.edu.sa/hmcan)


# HMMCan explicitly corrects for copy number bias and GC-content





# HMCan uses FREEC's algorithm for annotation of copy number alterations





Copy number profile for HeLa-S3 cell line obtained using the Input data (ENCODE dataset)



# Read densities profiles are corrected for copy number




# HMCan subtracts the control (input) density from the ChIP density








# HMCan applies Hidden Markov Models to extract the signal



Normalized density  $\Rightarrow$  “Yes-No” Signal



# Peaks predicted by HMCAN for ENCODE data do not show copy number bias




# Framework for the analysis of histone modification profiles & TFBSs [nebula.curie.fr](http://nebula.curie.fr)





- Nebula: web-service for analysis of ChIP-seq data

The screenshot shows the Nebula web service interface in a browser window. The browser address bar displays 'nebula.curie.fr'. The page features a dark navigation bar with the Nebula logo and menu items: 'Analyze Data', 'Workflow', 'Shared Data', 'Help', and 'User'. A 'Using 3%' indicator is visible on the right. The main content area is titled 'Welcome to Nebula' and includes the Institut Curie logo with the tagline 'Ensemble, prenons le cancer de vitesse.' Below the title, there is a paragraph explaining that Nebula is a web service provided by Institut Curie and powered by Galaxy, designed for ChIP-seq data analysis. It also provides instructions for users who have not used Galaxy, including a link to a tutorial. A section titled 'Tools' lists various NGS tools such as 'NGS: QC', 'NGS: Motif Discovery', 'NGS: Mapping', 'NGS: SAM Tools', 'NGS: BED Tools', 'NGS: Peak Calling', 'NGS: Peak Annotation', and 'NGS: SVDetect'. On the right side, a 'History' panel shows a list of recent analyses, including 'Input for H3K27me3 chr1.sorted.noDup.bam' and 'H3K27me3 chr1.sorted.noDup.bam', with a total size of 540.8 Mb.


# Nebula: web-service for analysis of ChIP-seq data




## Statistics for external connections to Curie



# Nebula: web-service for analysis of ChIP-seq data




- Peak calling
- Calculation of the density and cumulative distribution of peak locations relative to gene transcription start sites
- Annotation of peaks with genomic features and genes with peak information





Some graphs produced produced by Nebula.

# 3D structure of the genome is related to the epigenetic profiles




- Lamina associated domains (LAD) affect gene expression

Model of chromosome organization in interphase






# 3D structure of the genome is related to the epigenetic profiles



- Lamina associated domains (LAD) affect gene expression
- 82% of the H3K9Me2 LOCKs overlap with the locations of LADs
- H3K9 methyltransferase G9a is a regulator of NL contacts




J.G. van Bemmelen et al., *PLoS ONE*, 2010


B. Wen et al., *Nat Genet.*, 2009

J. Kind et al., *Cell*, 2013

# The technique DamID can be used to get genome-wide profiles for lamina binding




- The enzyme **Dam (green)** is fused to the **protein of interest (orange - lamin)** by expression of a chimeric DNA sequence.
- **The protein of interest** drags **Dam** onto its cognate targets.
- The tethering leads to methylation of GATCs in the neighborhood of the binding site (red) but not at a distance.




**Methylation tag** can be detected using restriction enzymes (DpnI and DpnII)


# 3D structure of the genome defines regulatory interactions between promoters and enhancers




- Scales of genome architecture




# 3D structure of the genome defines regulatory interactions between promoters and enhancers



- 3C, 4C, 5-C and Hi-C methods allow mapping 3D interactions of chromatin




In some cases, it is even possible to reconstruct the 3D structure using hi-C interactions maps




- Physical Modeling of the Chromatin Fiber


5C in mouse ESCs




Polymer modeling



High-resolution DNA/RNA FISH




# Disruption of genomic sequence can lead to the disruption of TAD and changes in the regulation of gene expression




CTCF-mediated TAD boundaries and intra-TAD genomic organization via long-range interactions

Blurring of TAD boundaries after deletion of a 50–80 kb boundary between TADs that contains CTCF and active genes






# Disruption of the genomic sequence in cancer can affect epigenetic profiles



- Mutations and structural variants (SVs) in cancer genomes →
  - Disruption of epigenetic profiles by mutation of epigenome-regulatory proteins (readers, writers or erasers)
  - Disruption of regulatory elements
  - Disruption of TAD/LAD structure
  - Disruption of interactions between genes and regulatory elements





# Changes in histone variant profiles can also happen in cancer




- Mutations in H3.3-ATRX-DAXX chromatin remodelling pathway were identified in 44% of glioblastomas (mostly high grade paediatric glioblastomas)
- Alternate lengthening of telomere (ALT) is associated with the presence of mutant H3F3A/ATRX

*ATRX* and *DAXX* encode two subunits of a chromatin remodelling complex required for H3.3 incorporation at pericentric heterochromatin and telomeres




|              | ATRX IHC-positive | ATRX IHC-negative |
|--------------|-------------------|-------------------|
| ALT-negative | 75                | 8                 |
| ALT-positive | 10                | 37                |

# Changes in histone variant profiles can also happen in cancer




- Mutations in H3.3-ATR-X-DAXX chromatin remodelling pathway were identified in 44% of glioblastomas (mostly high grade paediatric glioblastomas)
- The number of CNAs per tumour is higher in samples with *H3F3A/ATR-X-DAXX/TP53* mutations)

*ATR-X* and *DAXX* encode two subunits of a chromatin remodelling complex required for H3.3 incorporation at pericentric heterochromatin and telomeres




# Summary



- Chromatin is organised in LAD and TAD, related to histone modifications DamID Hi-C, 5-C, 4-C,...
- Histone modifications/histone variants have direct effect on gene transcription Regression & Machine learning
- Histone modifications form groups and indicate distinct chromatin states ChIP-seq Hidden Markov Models
- Epigenetic states change in cancer compared to normal ancestral cells (>30 epigenome-modifying proteins can be mutated in different cancers)

# Summary



- Epigenetic states change in cancer compared to normal ancestral cells
  - Loss of imprinting
  - Hypermethylation of CpG islands of tumor suppressor genes
  - Genome-wide DNA hypomethylation
  - Long Range Epigenetic Silencing (LRES)
  - Large organized chromatin-lysine-(K) modifications (LOCKS)
  - Disruption of TADs and LADs
  - Depletion of histone variant H3.3 in pericentric heterochromatin and telomeres resulting in alternate lengthening of telomere (ALT) and increased number of copy number alterations